Goodwin advised DeuteRx on its agreement to sell DRX-065, a novel clinical stage drug candidate, to Poxel SA for $8 million (€6.8 million). In addition, Poxel…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
